STAAR Surgical Company (STAA) vs First Tracks Biotherapeutics Inc (TRAX)

A side-by-side comparison of STAAR Surgical Company and First Tracks Biotherapeutics Inc across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — STAA vs TRAX

growth of $100 · dividends reinvested · last 1y
STAA +20.7% (+20.7%/yr)TRAX +73.6% (+73.6%/yr)TRAX compounded faster over this window
100150200250Start $100$121$174
STAA TRAX

STAA vs TRAX: by the numbers

  • •STAA is the larger company ($1.10B vs $1.10B market cap).
  • •STAA is profitable (1.13% net margin) while TRAX runs a net loss (0.00%).

Metrics side by side

Valuation

MetricSTAATRAX
P/E ratio276.87N/A
Forward P/E76.31N/A
P/S ratio3.25N/A
P/B ratio3.026.49
EV / EBITDA22.47N/A

Profitability

MetricSTAATRAX
Gross margin76.23%0.00%
Operating margin-19.19%0.00%
Net margin1.13%0.00%
ROE1.05%-57.77%
ROIC4.80%-59.76%

Growth (annualized)

MetricSTAATRAX
Revenue CAGR (5Y)10.49%N/A
Total return CAGR (5Y)-28.41%N/A

Frequently asked

Is STAA or TRAX more profitable?
STAA runs the higher net margin — STAA at 1.13% versus TRAX at 0.00%.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.